Takeshima, Takao http://orcid.org/0000-0003-2678-6956
Doi, Hikaru
Ooba, Satomi
Tanji, Yuka http://orcid.org/0000-0001-7850-1946
Ozeki, Akichika http://orcid.org/0000-0001-5510-4219
Komori, Mika http://orcid.org/0000-0003-1887-1296
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study
https://doi.org/10.1007/s40120-024-00602-z
Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
https://doi.org/10.1007/s40120-023-00534-0
Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
https://doi.org/10.1007/s40120-022-00410-3
Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
https://doi.org/10.1007/s40120-021-00236-5
Documents that mention this clinical trial
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study
https://doi.org/10.1007/s40120-024-00602-z
Funding for this research was provided by:
Eli Lilly Japan (Study funding, funding for Rapid Service/Open Access fees, funding for medical writing assistance)
Daiichi-Sankyo (Funding for medical writing assistance only)
Article History
Received: 29 November 2023
Accepted: 8 March 2024
First Online: 6 April 2024
Declarations
:
: Takao Takeshima received research funding/collaborative research expenses from Biohaven, Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Lundbeck Japan K.K., and Shionogi & Co., Ltd., and reports personal fees from Amgen K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Takao Takeshima also acted as an advisor to Hedgehog MedTech, Inc. and Sawai Pharmaceutical Co., Ltd. Hikaru Doi acted as an advisor to Amgen K.K. and Otsuka Pharmaceutical Co., Ltd.; reports research funding from AbbVie GK, Allergan, Inc., Amgen K.K., Biohaven, Ltd., Eli Lilly Japan K.K., Lundbeck Japan K.K., Otsuka Pharmaceutical Co., Ltd., and Pfizer Japan Inc.; and received personal fees from Amgen K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Satomi Ooba reports personal fees from Amgen K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Yuka Tanji, Akichika Ozeki, and Mika Komori are employees of Eli Lilly Japan K.K. and are shareholders in Eli Lilly and Company.
: The protocols for both trials were reviewed and approved by local ethics review boards, and written informed consent was obtained from all patients before participation. Both studies were conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. A list of the institutional ethics review boards is provided in Table .